Company Information

  

Address: 55 CAMBRIDGE PARKWAY
SUITE 100 
City: CAMBRIDGE 
State: MA 
Zip Code: 02142 
Telephone: 760-603-2732 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a late-stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. Our goal is to become the premier company offering treatments for these inadequately treated diseases. We are advancing a mature pipeline of four novel drugs with the potential to treat multiple diseases. Our drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc., or Ionis, which owns approximately 68% of our outstanding common stock. Our most advanced drug, volanesorsen, is currently under review by regulatory agencies in the United States, or U.S., European Union, or EU, and Canada for the treatment of people with familial chylomicronemia syndrome, or FCS.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/2018-3.26NAN/E
12/2017-2.82NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.24Total Liab/Total Assets0.33
Net Inc/Total Assets-0.41Total Liab/Inv Cap0.47
Net Inc/Inv Cap-0.58Total Liab/Comm Equity0.19
Pretax Inc/Net Sales-1.96Interest Coverage Ratio-61.67
Net Inc/Net Sales-1.99Curr Debt/EquityNA
Cash Flow/Net Sales-0.66LTD/EquityNA
SG&A/NetSales0.67Total Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables Turnover20.40Quick Ratio3.30
Inventory TurnoverNACurrent Ratio3.30
Inventory Day SalesNANet Rec/Curr Assets0.02
Net Sales/Work Cap0.30Inv/Curr AssetsNA
Net Sales/PP&E717.00  

Income Statement (Millions)

  3/31/2018 12/31/2017 9/30/2017 6/30/2017
Total Revenues(Net Sales) 17.11 18.04 13.45 17.63
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 19.47 17.02 8.37 6.91
Operating Income -30.33 -24.95 -12.56 -7.77
Interest Exp 0.00 0.00 0.22 0.97
Pretax Income -29.63 -24.15 -12.03 -8.44
Other Income 0.70 0.80 0.76 0.30
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -29.63 -23.36 -14.09 -8.44

Balance Sheet (Millions)

Assets 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Cash & Short Term Investments 244.94 260.13 286.13 118.67
Receivables - Total 0.00 5.41 0.50 NA
Inventories - Total NA NA NA NA
Total Current Assets 250.56 266.85 287.88 122.61
Net Property, Plant & Equipment 0.05 0.08 0.10 0.11
Total Assets 252.47 268.80 289.35 124.10
Liabilities        
Accounts Payable 47.50 28.40 17.27 14.85
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 98.30 80.85 73.46 69.05
Long-Term Debt NA NA NA 107.51
Total Liabilities 106.17 89.17 91.51 207.09
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA 0.00 0.00 100.00
Common Stock 0.07 0.07 0.07 0.00
Retained Earnings -325.85 -284.41 -261.05 -246.96
Treasury Stock NA NA NA NA
Total Stockholders' Equity 146.30 179.63 197.84 -82.98
Total Liabilities and Stockholders' Equity 252.47 268.80 289.35 124.10

Cash Flow Summary (Millions)

Categories 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Net Cash Provided by Operating Activities -16.76 -24.52 -17.68 -20.16
Net Cash Provided by Investing Activities 26.54 -26.41 -132.81 3.33
Net Cash Provided by Financing Activities 1.72 -0.98 185.41 14.43

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20150.00-61.42--
12/20160.00-83.22--
12/201755.21-109.75-2.82
Growth RatesInfinity----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/186920,52823.98




Report Date : 7/16/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.